Hepatocyte transplantation as a substitute strategy of orthotopic liver transplantation is being studied for treating end-stage liver diseases. Several technical hurdles must be overcome in order to achieve the therapeutic liver repopulation, such as the problem of insufficient expansion of the transplanted hepatocytes in recipient livers. In this study, we analyzed the application of FoxM1, a cell-cycle regulator, to enhance the proliferation capacity of hepatocytes. The non-viral sleeping beauty (SB) transposon vector carrying FoxM1 gene was constructed for delivering FoxM1 into the hepatocytes. The proliferation capacities of hepatocytes with FoxM1 expression were examined both in vivo and in vitro. Results indicated that the hepatocytes with FoxM1 expression had a higher proliferation rate than wild-type (WT) hepatocytes in vitro. In comparison with WT hepatocytes, the hepatocytes with FoxM1 expression had an enhanced level of liver repopulation in the recipient livers at both sub-acute injury (fumaryl acetoacetate hydrolase (Fah) -/-mice model) and acute injury (2/3 partial hepatectomy mice model). Importantly, there was no increased risk of tumorigenicity with FoxM1 expression in recipients even after serial transplantation. In conclusion, expression of FoxM1 in hepatocytes enhanced the capacity of liver repopulation without inducing tumorigenesis. FoxM1 gene delivered by non-viral SB vector into hepatocytes may be a viable approach to promote therapeutic repopulation after hepatocyte transplantation.
, J-X Li 1, 2 Hepatocyte transplantation as a substitute strategy of orthotopic liver transplantation is being studied for treating end-stage liver diseases. Several technical hurdles must be overcome in order to achieve the therapeutic liver repopulation, such as the problem of insufficient expansion of the transplanted hepatocytes in recipient livers. In this study, we analyzed the application of FoxM1, a cell-cycle regulator, to enhance the proliferation capacity of hepatocytes. The non-viral sleeping beauty (SB) transposon vector carrying FoxM1 gene was constructed for delivering FoxM1 into the hepatocytes. The proliferation capacities of hepatocytes with FoxM1 expression were examined both in vivo and in vitro. Results indicated that the hepatocytes with FoxM1 expression had a higher proliferation rate than wild-type (WT) hepatocytes in vitro. In comparison with WT hepatocytes, the hepatocytes with FoxM1 expression had an enhanced level of liver repopulation in the recipient livers at both sub-acute injury (fumaryl acetoacetate hydrolase (Fah) -/-mice model) and acute injury (2/3 partial hepatectomy mice model). Importantly, there was no increased risk of tumorigenicity with FoxM1 expression in recipients even after serial transplantation. In conclusion, expression of FoxM1 in hepatocytes enhanced the capacity of liver repopulation without inducing tumorigenesis. FoxM1 gene delivered by non-viral SB vector into hepatocytes may be a viable approach to promote therapeutic repopulation after hepatocyte transplantation. Hepatocyte transplantation has been studied for decades as a substitute way of therapy to orthotopic liver transplantation for treating end-stage liver diseases. 1 Although transplanted hepatocytes have been shown to engraft in recipient livers, 2 and repopulation of up to B2% of the liver has been reported, 3 it is not yet clear whether there is any clinical benefit to transplantation. A method to expand transplanted hepatocytes inside receipt livers would render hepatocytes more suitable for liver repopulation. 4 With a selective advantage over the host liver cells, the transplanted hepatocytes could efficiently expand to a level that may lead to a therapeutic benefit. Two strategies could be used to achieve selective advantage of transplanted hepatocytes. The first one is either to suppress host liver cell proliferation through blocking their regenerative capacity by retrorsine 5 or induce death in host cells, which happens in the uPA transgenic mouse 6 or fumaryl acetoacetate hydrolase (Fah) knockout mouse (Fah À / À mice). 1 However, this strategy is hard to apply in clinical situations. The second one is to selectively enhance the growth and survival of transplanted hepatocytes by activating pathways that regulate the cell cycle to generate 'superhepatocytes' with augmented proliferation capacity. With an enhanced capacity of proliferation, hepatocytes from knockout mice of cell cycle inhibitor p27 resulted in an improved efficiency of liver repopulation in livers of recipient mice. 7 This finding proved that the principle of manipulating pathways of cell cycle could be used for promoting the liver repopulation of transplanted hepatocytes. Expression of positive regulators of the cell cycle could also be applied for the purpose of promoting the liver repopulation of transplanted hepatocyte.
Forkhead box M1 (FoxM1) protein has been considered as one candidate for promoting expansion of donor hepatocytes in order to reach therapeutic liver repopulation. 8 Known as a key cell-cycle regulator of both G1/S phase transition and G2/M transition, 9 FoxM1 is highly expressed in most embryonic tissues. FoxM1 is necessary for hepatoblast mitosis and development of intrahepatic bile ducts and vessels during liver morphogenesis. 10 Hepatocytes with sustained expression of FoxM1 enter into S phase at least 8 h earlier than wild-type (WT) hepatocytes after partial hepatectomy. 11 On the other hand, inactivation of FoxM1 in liver reduces the level of hepatocyte DNA replication and blocks mitosis during mouse liver regeneration. 12 In livers of old mice, growth hormoneinduced FoxM1 expression restores normal levels of liver regeneration after partial hepatectomy. 13 Similarly, FoxM1 expression through adenovirus-based gene delivery restores liver regeneration in old mice, which is mediated by both decreasing p27 activity and increasing activity of cell cycle agonists Cdc25B.
14 These collective findings strongly support the potential application of FoxM1 to promote donor hepatocytes proliferation to compete with host hepatocytes during liver regeneration. A previous report indicated that hepatocytes of FoxM1 transgenic mouse had greater repopulation capacity than WT hepatocytes in host livers of uPA/SCID mice subjected to liver injury. 15 This finding suggested there is an advantage to hepatocytes with sustained expression of FoxM1 for various situations in which repopulation occurs. With a proper method to deliver into donor hepatocytes, FoxM1 may be used to promote donor hepatocyte expansion after cell transplantation.
Here, we confirmed that transgenic hepatocytes with sustained FoxM1 expression have enhanced capacity for liver repopulation in the Fah À / À mice recipients with induced host hepatocyte death and also in the Fah À / À mice recipients with normal healthy hepatocytes after partial hepatectomy. Sleeping beauty (SB) transposon vector has been regarded as one of most promising gene delivery system of gene therapy 16 and has already been used in clinical trials. 17 We constructed a SB transposon vector containing a FoxM1 gene to deliver it into hepatocytes before cell transplantation. The proliferation capacities of hepatocytes with FoxM1 expression were examined both in vivo and in vitro, in order to test possible applications of FoxM1 for future therapeutic purposes in liver repopulation.
Results
Hepatocytes with constitutive FoxM1 expression repopulated host livers more rapidly. Previous results have shown that Fah À / À mice undergo repopulation with WT hepatocytes upon induction of hepatocyte injury by withdrawal of the drug NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). 18 We expected to get the similar results with hepatocytes from TTR-FoxM1 transgenic mice, as previous results showed a significantly higher efficiency of liver repopulation than WT hepatocytes in the uPA mouse model of liver injury. 15 We isolated donor hepatocytes with sustained expression of human FoxM1 under the control of liver specific transthyretin (TTR) promoter from TTR-FoxM1 transgenic mice 11 to examine whether FoxM1 enhances liver repopulation in Fah À / À mice. As donor hepatocytes had a strain background that is different than Fah À / À mice, we used immunodeficient Fah À / À Rag-2 À / À mice as hosts to avoid immune rejection. 19 In all, 2 Â 10 5 TTR-FoxM1 hepatocytes were injected into the spleen of hosts. The same amount of b-gal þ hepatocytes from Rosa26-LacZ mice were used as a control for hepatocytes without ectopic FoxM1 expression.
The level of liver repopulation was determined at 2, 4, 6 and 8 weeks after hepatocyte transplantation. Repopulation nodules from TTR-FoxM1 hepatocytes could be observed in the livers of Fah À / À Rag-2 À / À recipients ( Figure 1a ). In comparison with b-gal þ hepatocytes, TTR-FoxM1 hepatocytes repopulated host liver to the higher levers at 2, 4 and 6 weeks after transplantation (Figures 1b and c) . Although there is no significant difference in the levels of complete liver repopulation between two kinds of hepatocytes at 8 weeks after transplantation and afterward, the higher proliferation rate of FoxM1 þ hepatocytes made it possible that TTRFoxM1 hepatocytes could complete liver repopulation 2 weeks ahead of the b-gal þ hepatocytes. Next, a method of competitive repopulation 20 was used to compare the capacity for liver repopulation between TTRFoxM1 hepatocytes and b-gal þ hepatocytes during liver repopulation. TTR-FoxM1 hepatocytes and b-gal þ hepatocytes were mixed at a 1 : 1 ratio, and 2 Â 10 5 mixed hepatocytes were transplanted into livers of Fah À / À Rag-2 À / À mice. Southern blot analysis was previously used to quantitatively determine the contribution of each type of donor hepatocyte to liver repopulation. 20 We applied this analysis for competitive repopulation in our study. At each time point during liver regeneration, TTR-FoxM1 hepatocytes contributed a greater amount of donor cell DNA than b-gal þ hepatocytes (Figure 1d ). At 8 weeks after completing liver repopulation, TTR-FoxM1 hepatocytes contributed 70% ± 5%, while b-gal þ hepatocytes only contributed 22%±8% (Figure 1d ). Furthermore, a direct comparison between TTR-FoxM1 hepatocytes and b-gal þ hepatocytes was studied in WT recipient mice with partial hepatectomy (PHx). In all, 2 Â 10 5 equally mixed TTR-FoxM1 hepatocytes and b-gal þ hepatocytes were transplanted into the livers of WT mice that were treated with standard 2/3 PHx. The result also showed an enhanced capacity for liver repopulation with TTR-FoxM1 hepatocytes. TTR-FoxM1 hepatocytes contributed 5-8% of total hepatocytes in regenerated livers after PHx, while b-gal þ hepatocytes were o1% of the total (Figure 1e ).
In summary, TTR-FoxM1 enhances hepatocyte proliferation compared with WT hepatocytes.
FoxM1 can be effectively delivered into hepatocytes in vivo. We have established a facile method for delivering multiple genes to somatic hepatocytes using SB transposon system, 21, 22 and have found that the SB transposon system is effective in delivering genes into hepatocytes. In the following experiments, pKT2/FAH-hFoxM1-SB was constructed in which a CMV enhancer/chicken b-actin promoter/b-globin intron fusion sequence (Caggs) regulates expression of human FoxM1 gene, and SV40 promoter regulates expression of Fah gene from the same transcript. The Fah gene was delivered to correct metabolic deficiency in hepatocytes of Fah À / À mice. In addition, a PGK promoter-driven SB transposase gene is outside of the transposon in the same plasmid. A vector with a reversed FoxM1 gene (pKT2/FAHrhFoxM1-SB) was used as control. A schematic summarizing of the plasmid construction is shown in Figure 2a .
FoxM1 SB vectors were delivered into hepatocytes of Fah À / À mice by hydrodynamic tail vein injection. Results of immunohistochemistry (IHC) in the same section indicated hepatocytes at all time points that the activity of liver repopulation had not completed. Expression of both FAH and FoxM1 protein was proven in the repopulated livers by western blots (Figure 3c ). Therefore, the enhanced capacity of liver repopulation of Fah À / À mice reflected the enhanced cell expansion capacity of the hepatocytes with SB delivered FoxM1 gene. Moreover, results of functional studies indicated that the levels of aspartate aminotransferase, alanine transaminase and total bilirubin of FoxM1 hepatocytes recipients were recovered to normal ranges (Figure 3d ), suggesting that the liver functions of mice recipients were effectively restored.
Next, we analyzed whether FoxM1 gene delivered by SB could enhance liver repopulation after partial hepatectomy. Fah À / À mice were maintained on continuous NTBC, which maintains the liver in a healthy state. 24 In all, 2 Â 10 5 FAH þ FoxM1 þ hepatocytes or the same amount of WT hepatocytes were transplanted into healthy Fah À / À mice that underwent 2/3 PHx, with NTBC provided throughout. Results of costaining of FAH and FoxM1 protein expression levels showed that the 2/3 PHx livers were significantly repopulated by FAH þ FoxM1 þ hepatocytes (Figure 3e) . Results of FAH immunoassay revealed that FAH þ FoxM1 þ hepatocytes amounted up to 15.6% of total hepatocytes (range 5.8 to 15.6%, average 6.16% at 3 weeks and from 4.5 to 11.8% average 7.02% at 6 weeks). In comparison, significant lower (Figures 3f and g ). In addition, the FAH þ FoxM1 þ hepatocytes were cultured and detected for DNA replication by using the time course of BrdU incorporation. The result indicated that during 24-48 h of cell culture, more FoxM1 þ hepatocytes than WT hepatocytes incorporated BrdU, indicating a faster entry into S-phase by FoxM1 þ cells (Figure 4a ). Ki67 and proliferating cell nuclear antigen (PCNA) were used as cell proliferation markers to further evaluate the proliferation rate in order to confirm the result of BrdU incorporation. The Ki67 þ cells in total FoxM1 þ hepatocytes 
were significantly higher than those in WT hepatocytes after 30 h of culture. The same result was also obtained from the experiments with proportions of PCNA (Figures 4b and c) . However, the expression levels of cyclin D1 in every time point were not elevated (Figure 4d ), same as finding in a previous report. 25 These results showed a consistent enhancement of FoxM1 hepatocyte expansion was induced by the activation of pathway relative to Ki67 and PCNA, but not Cyclin D1. 25 Liver repopulation by hepatocytes with ex vivo FoxM1 gene delivery by SB vector. Modified hepatocytes with an enhanced proliferation capacity could be used for cell transplantation therapy in the future. Ex vivo gene delivery of FoxM1 by SB vector into hepatocytes was tested in our experiment. The SB vector of pKT2/GFP-hFoxM1-SB, which contains FoxM1 and GFP genes, was constructed and used to transfect freshly isolated WT hepatocytes in cell culture. 
FoxM1
þ hepatocytes did not form tumors. The risk of cancer formation is a concern for any therapies that involve integration in the genome and enhancement of cell proliferation. To evaluate the safety of overexpressing FoxM1, we serially isolated and transplanted FoxM1-expressing hepatocytes at 8-week intervals up to four times, resulting in continuous proliferation of the cells for 8 months. No tumor was found in all tissues of the mice recipients, and the livers of recipients kept in the normal morphological structure and size with healthy sinusoidal plates (Figure 6a) . Particularly, liver tissues repopulated by TTR-FoxM1 hepatocytes showed normal liver sinusoidal structures without any morphological abnormalities although TTR-FoxM1 hepatocytes divided at least 44 times during the four rounds of serial transplantations (Figure 6a) . Furthermore, hepatocytes isolated from TTR-FoxM1 mice did not form tumors 12 weeks after subcutaneous xenograft in NOD/SCID mice (Figure 6b ). We observed similar results with FoxM1 þ hepatocytes delivered using SB gene delivery. In all, 20 Fah À / À mice injected with FoxM1-SB plasmids, the livers showed normal morphological structure and size, and no tumor were found in all liver samples harvested at 8 weeks (Table 2) , even with repopulation levels as high as 68.03% (Figure 6c ). In addition, no tumor was found in any secondary recipient mice until 18 months after transplantation when liver repopulation totally completed in liver of recipients (Table 2 ).
In addition, gene expression levels were analyzed in repopulation nodules of FAH þ hepatocytes. The FAH Therefore, these results confirmed that there was no the risk of tumorigenesis with SB-mediated FoxM1 delivery during the span of our experiments in the liver injury models and immunodeficient animals.
Discussion
Previous clinical trials of hepatocyte transplantation suggest that a level of 42% engraftment is necessary to reach therapeutic benefit for different metabolic disorders. 3, 30 However, at present it is hard to reach such level with unmodified human hepatocytes. 3 Recent publications showed increased engraftment after irradiation to inhibit host hepatocyte proliferation, 31 or 4-[(2-carboxyethyl)-hydroxyphosphinyl]-3-oxobutyrate (CEHPOBA) as metabolic enzyme inhibitor to simulate metabolism disorders. 32 But those methods also may have strong side effects to patients. In comparison, using a regulator of cell cycle to modify donor hepatocytes is a more promising approach.
FoxM1 was chosen in our study for its ability to accelerate the cell cycle in donor hepatocytes during liver regeneration without tumorigenesis. 33 On the other hand, a safe and reliable gene delivery system is another important issue to be considered in our study. The non-viral SB transposon/ transposase system has many advantages over other nonviral DNA vectors, 34 such as higher transgene integration rate, without plasmid sequences integration that silence transgene expression and no integration of transgene concatemers. Especially, the high cargo capacity of SB vector system 35 allowed our designed construct for ideal delivery and sustained FoxM1 expression. In the previous reports, 22 the transfection efficiency of SB transposon system was known approximately 2%, which was defined as the rate of DNAs inserted into genome of liver cells. Our transfection efficiency of SB delivered FoxM1 was similar to previous reports. 36 Here, the selection of donor hepatocytes from liver regeneration mechanism during liver injury, such as in Fah À / À mice and in 2/3 PHx mice, made an efficient expansion of FoxM1 þ hepatocytes in the host livers. The result suggested the potential advantage could be obtained from the combination of enhanced cell proliferation by FoxM1-SB gene delivery and selection power of liver repopulation, which could become the potential future clinical application.
Previous studies indicated that 2/3 partial hepatectomy, used in combination with cell transplantation, promoted engraftment and cell expansion of transplanted donor hepatocytes. We found that mice undergoing PHx showed much higher liver engraftment from FoxM1 þ hepatocytes than from WT hepatocytes. Moreover, our results revealed that enhanced capacity of cell proliferation for FoxM1 þ hepatocytes greatly reduced the amount of time needed to complete liver repopulation in Fah À / À mice, which could be considered as an advantage to using FoxM1 in future applications.
Our study also indicated that the FoxM1 enhanced hepatocyte proliferation during liver repopulation was through both PCNA and Ki67 involved signaling pathway, but not cyclin D1 involved one. Our finding is same with results of previous report. 25 We presumed that the possible mechanism of FoxM1 in acceleration of G2/M phase transition could be by stimulating the cell cycle regulators other than cyclin D1.
Although it was previously shown in TTR-FoxM1 transgenic mice that hepatocytes with expression of FoxM1 did not have an elevated incidence of tumors for hepatocellular carcinoma during induction, 33 it was not proved yet whether transplanted hepatocytes with constitutive FoxM1 expression, undergoing extensive liver repopulation, would form tumors. Furthermore, hepatocytes with transposonmediated delivery of FoxM1 should be studied carefully for tumorigenicity before consideration for future clinical application. Therefore, we deeply analyzed the tumorigenesis from the TTR-FoxM1 hepatocytes undergoing continuous cell division by serial transplantation. Our results showed that there were no tumors formed in any recipient mice and no morphological abnormalities in TTR-FoxM1 hepatocytes. In addition, TTR-FoxM1 hepatocytes did not form any tumor after subcutaneous xenograft in NOD/SCID mice. In our study, we also had broad scanning of the sufficient liver samples from the recipients with high level of liver repopulation after FoxM1 SB plasmid injection. On the other hand, we have not found the existence of risk of tumorigenesis in 
FoxM1
þ hepatocytes even at 18 months after the gene delivery.
We have found an efficient method to genetically modify primary hepatocytes by SB vector delivery. Hepatocytes with FoxM1 expression demonstrated the enhanced capacity of proliferation in both in vitro and in vivo. We also expect that this method can be used for modifying other hepatic cells, such as hepatocytes derived from ES/iPS cells, 37, 38 hepatocytes or hepatic stem cells trans-differentiated from other kinds of cells, 27, 39 which are being studied for future applications of cell transplantation therapy.
Materials and Methods
Mouse strains and animal husbandry. TTR-FoxM1 transgenic mice were kindly provided by Dr. Robert Costa. Fah À / À and Fah À / À Rag2 À / À mice were maintained with drinking water containing NTBC at a concentration of 7.5 mg/ml. All mice were housed in individually ventilated cage system under special pathogen-free facility with barrier conditions, and animal care was in accordance with institutional guidelines.
Hepatocytes isolation, competitive repopulation experiment, partial hepatectomy surgery, serial transplantation and FACS.
Mice were subjected to standard two-step collagenase perfusion for primary hepatocytes isolation. Parenchymal cells were purified by Percoll buffer (90% Percoll (Sigma-Aldrich, St. Louis, MO, USA), EBSS) at low-speed centrifugation (1500 r.p.m., 10 min). Viability of isolated hepatocytes was determined by Trypan blue stain.
In competitive repopulation experiments, mixed hepatocytes (TTR-FoxM1 hepatocytes: b-gal þ hepatocytes ¼ 1 : 1) were transplanted into Fah À / À Rag-2 À / À mice. At 2, 4, 6 and 8 weeks after transplantation, liver tissues were harvested from recipients for analysis by Southern blot. Liver genomic DNA was isolated from random sections of tissue from the left main lobe. Genomic DNAs were digested with BamHI (Takara, Dalian, China) and separated by 0.8% agarose gel. Capillary transfer and hybridization were performed according to standard protocols. Detection of FoxM1 and LacZ genes indicate repopulation contributed by TTR-FoxM1 and Rosa26-LacZ hepatocytes, respectively.
For serial transplantation, TTR-FoxM1 hepatocytes were isolated from the liver of primarily transplanted Fah À / À Rag-2 À / À mice at 8 weeks when complete liver repopulation has reached. The 10 5 TTR-FoxM1 hepatocytes from primary recipient were transplanted into the secondary recipients of Fah À / À Rag-2 À / À mice, and the second round of liver repopulation was studied. After next 8 weeks, TTR-FoxM1 hepatocytes were harvested again and re-transplanted into third group of Fah À / À Rag-2 À / À mice. Serial transplantation lasted four rounds. PHx was acted as described. 40 In all, 2 Â 10 5 hepatocytes were injected immediately into the spleens of mice recipients. Fah À / À mice that was subjected to PHx were maintained with NTBC. To those recipients without PHx, NTBC was withdrawn from the drinking water after cell transplantation.
For FACS, hepatocytes were harvested and washed twice in washing buffer (phosphate-buffered saline containing 0.2% BSA). In all, 10 5 cells were stained in 100 ml washing buffer with chromophore-conjugated antibodies at 4 1C for 30 min, washed twice and analyzed. Primary antibody-bound cells were further incubated with PE-conjugated secondary antibodies at 4 1C for 30 min, washed twice and analyzed. Isotope antibodies were used as negative controls. Cells were harvested and washed twice. Cells were analyzed using a FACS Calibur flow cytometer (Becton Dickinson, San Jose, CA, USA) and data analyzed via FlowJo software (Tree Star, Ashland, OR, USA).
Plasmids construction, tail vein injection and in vitro transfection. We modified the plasmid, pKT2/FAH-IRES-Luc-SB, described in our previous study 22 to construct plasmid for transporting FoxM1. Human FoxM1 gene was cloned and substituted Fah gene to get pKT2/hFoxM1-IRES-Luc-SB. Then SV40-FAH was inserted into the plasmid to construct pKT2/FAH-hFoxM1-IRESLuc-SB. IRES-Luc was cut off from plasmid pKT2/FAH-hFoxM1-IRES-Luc-SB. Plasmid pKT2/FAH-hFoxM1-SB were used for transport FoxM1 and Fah genes into hepatocytes by tail vein injection. Luciferase gene in pKT2/hFoxM1-IRES-Luc-SB was substituted with GFP gene to get the plasmid used in in vitro transfection.
For tail vein injection, 30 g high-quality plasmid diluted in 1/10 body weight Ringer's solution, injected into Fah À / À mice through tail vein within 10 s. Highly purified plasmid was transfected into fresh isolated WT hepatocytes with Amaxa-Mouse/Rat-Hepatocyte-Nucleofector-Kit (Lonza, Basel, Switzerland) followed the optimized protocol from manual.
IHC and immunohistofluorescence. Immunohistologic detection of FAH, as well as hematoxylin and eosin staining were preformed. Liver samples were fixed in 4% paraformaldehyde before paraffin embedding. Sections (2 mm) were de-paraffin with xylene, rehydrated, incubated with rabbit anti-mouse Fah primary antibody (HepatoScience, San Jose, CA, USA) at 37 1C for 1 h, then horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G secondary antibody, followed by detection with DAB (Dako, Glostrup, Denmark) and counterstaining with Mayer's hematoxylin solution (Sigma-Aldrich).
Donor cells and their descendants were labeled by anti-FAH IHC. Liver repopulation rates were evaluated by calculating the ratio of FAH þ area in whole liver sections. For immunohistofluorescence, sections were incubated with rabbit anti-mouse Fah AB mixed with mouse anti-human FoxM1 primary antibody (Abcam, Cambridge, MA, USA), followed by donkey anti-rabbit Dylight t 488-conjugated and goat anti-mouse Dylight549-conjugated secondary antibody at 37 1C for half an hour in dark. Nuclei were stained with Dapi-Fluoromount-G (Sourthernbiotech, Birmingham, AL, USA).
Western blot. Western blot analysis was performed as previous publication. 22 Liver total proteins were extracted from mouse liver tissues using Minute Total Protein Extraction Kit (Invent Biotechnologies, Eden Prairie, MN, USA). For detection of FAH, rabbit anti-mouse FAH was used in combination with goat antirabbit IgG, HRP (Sigma-Aldrich). For detecting human FoxM1, rabbit anti-human FoxM1 (Lifespan, Seattle, WA, USA) was used as primary antibody with goat antirabbit IgG, HRP (Sigma-Aldrich) as secondary antibody. Mouse anti-cyclin D1 (Santa Cruz, Dallas, TX, USA) and goat anti-mouse IgG, HRP (Sigma-Aldrich) were used for detecting cyclin D1. To analyze the proliferation rate of mouse hepatocytes, we used primary hepatocyte culture conditions as previously described. 41 The percentage of cells undergoing DNA synthesis was estimated by counting the number of BrdU-labeled cells using the BrdU detection kit (Roche Diagnostics, Meylan, France). Cells were incubated with BrdU-labeling medium for 5 h. The medium was then removed, and cells were fixed in ethanol/acetic acid (7 : 3) and stained according to the manufacturer's instructions. Ten separate fields per plate were counted.
Cultured primary hepatocytes were fixed by 4% PFA, stained by rabbit anti-Ki67 (Thermo Fisher Scientific) and mouse anti-PCNA (Thermo Fisher Scientific) primary antibody, followed by donkey anti-rabbit Dylight488-conjugated and goat antimouse Dylight549-conjugated secondary antibody (Jackson ImmunoResearch, West Grove, PA, USA) at 37 1C for half an hour in dark. Nuclei were stained with Dapi-Fluoromount-G (Sourthernbiotech). The positive nuclei and DAPI in a field were counted, five separate fields per plate were counted. 
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